2013 EACPT Geneva Congress Symposia: Health Economic Assessment

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on Health Economic Assessment

Personalised medicine and pharmacogenetic testing add new insights in drug development. From 2014, all new branded medicines and diagnostic tools in some European countries will be priced according to their therapeutic value and wider benefits they may deliver. Under this value-based pricing (VBP) system, it is proposed that explicit weightings be attached to the health benefits (e.g. QALY gains) provided by medicines to reflect a broader range of relevant criteria. There is controversy as to which forms of benefits are to be weighted, and by how much. The transferability issues from a country to another one will be discussed.

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org